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Eleven laboratories evaluated the use of dried blood and plasma spots for quantitation of human immuno-
deficiency virus (HIV) RNA by two commercially available RNA assays, the Roche Amplicor HIV-1 Monitor
and the bioMerieux NucliSens HIV-1 QT assays. The recovery of HIV RNA was linear over a dynamic range
extending from 4,000 to 500,000 HIV type 1 RNA copies/ml. The Monitor assay appeared to have a broader
dynamic range and seemed more sensitive at lower concentrations. However, the NucliSens assay gave more
consistent results and could be performed without modification of the kit. HIV RNA was stable in dried whole
blood or plasma stored at room temperature or at 70°C for up to 1 year. Dried blood and dried plasma spots
can be used as an easy and inexpensive means for the collection and storage of specimens under field
conditions for the diagnosis of HIV infection and the monitoring of antiretroviral therapy.
Human immunodeficiency virus (HIV) RNA levels in blood
plasma are used to monitor the response to antiretroviral drug
therapy in developed countries. Since the International AIDS
Conference held in Durban, South Africa, in 2000, there has
been a global effort to provide access to antiretroviral drugs to
all infected individuals, including those in the resource-poor
countries which have been hit the hardest by the AIDS pan-
demic. Studies have demonstrated that the provision of treat-
ment is not enough, however. In order for the drugs to be most
effective, both for an individual and for public health reasons,
it will be necessary to monitor the responses to the therapy.
HIV RNA assays typically use plasma, which implies access to
laboratory equipment that may not be readily available in all
field settings. Therefore, alternative specimens must be con-
sidered for use in these situations.
Whole blood dried on filter paper (dried blood spots
[DBSs]) has been used to qualitatively detect HIV antibodies
(13, 15), HIV DNA (1, 3, 5–7, 9, 10, 11, 12, 16, 18) and HIV
RNA (4, 14, 17; J. L. Gerstel and A. M. Comeau, Proc. 10th
Natl. Neonatal Screening Symp., abstr. P-19, p. 64, 1994). In
addition, dried plasma spots (DPSs) have also been used to
quantitate the HIV load (8). Although the stabilities of anti-
bodies and DNA in DBSs have been determined (2, 6, 13),
there has been some question regarding the stability of the
HIV RNA when it is dried and stored at room temperature
(14, 17).
The purpose of this study was to compare two different
methods for quantitatively measuring HIV RNA in DBSs and
DPSs and to assess their long-term stability at room tempera-
ture and at 70C.
(This study was presented in part at the 12th World AIDS
Conference, Geneva, Switzerland, 28 June to 3 July 1998 [S.
Cassol, A. Comeau, S. Fiscus, G. Aldrovandi, J. Sullivan, J.
Bremer, and B. Jackson, Abstr. 12th World AIDS Conf., abstr.
33166, 1998].)
MATERIALS AND METHODS
Specimens. Three different panels were prepared by the Virus Quality Assur-
ance Laboratory by using filter paper (903; Schleicher & Schuell, Keene, N.H.)
spotted with 50 l of plasma or whole blood. The 903 filter paper is inexpensive,
available worldwide, and commonly used for assays for the screening of new-
borns (Guthrie cards) and has been used before for the detection of HIV
antibodies (2, 15), DNA (5–7, 9–12), and RNA (8, 14, 17). The spotted filter
papers were allowed to dry overnight at room temperature, placed in individual
ziplock bags containing a silica desiccant (MultiSorb Technology, Inc., Buffalo,
N.Y.), and then frozen at 30 or 70°C or stored at room temperature. Panels
1A and 2 were frozen at 30°C; panel 1B consisted of spots from panel 1A which
were subsequently thawed and stored at room temperature for 3 months prior to
retesting; panel 3 was stored at either 70°C or room temperature, with no
freeze-thaw events, for various lengths of time up to 52 weeks. All specimens
were coded to blind the laboratories.
Panel 1 consisted of seronegative plasma and whole blood, to which fivefold
serial dilutions of a well-characterized HIV type 1 (HIV-1) stock with from 0 to
500,000 copies/ml was added (nominal concentrations). Each specimen was
tested in duplicate by the participating laboratories, and each panel was tested at
two different time points (panels 1A and 1B).
Panels 2 and 3 each consisted of liquid plasma, DPSs, and DBSs from three
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HIV-1-infected patients and one uninfected patient, all in triplicate. For the six
HIV-1-infected patients (three different patients for each of the two panels), the
nominal concentrations determined by the Virus Quality Assurance Laboratory
by the Roche Diagnostics (Branchburg, N.J.) Amplicor HIV-1 Monitor assay
with liquid plasma were as follows: for panel 2, 1,157, 16,620, and 231,040
copies/ml, respectively; for panel 3, 1,064, 99,980, and 65,332 copies/ml, respec-
tively.
Panel 3 was designed to evaluate the stability of HIV RNA in DBSs and DPSs
during storage at room temperature and 70°C. Each panel consisted of tripli-
cate blood or plasma spots from four HIV-infected patients (12 spots for each
panel). One complete set (blood and plasma) was assayed at baseline. Four sets
(samples B and D) were placed in storage at room temperature, and the other
four sets (samples C and E) were stored at 70°C. One set of blood and plasma
spots from each storage condition was assayed after 2, 4, 26, and 52 weeks of
storage.
HIV-1 RNA assays. Assays for detection of HIV-1 RNA were conducted over
a 3-year period (September 1997 to June 2000), and multiple kit lots were used.
Three (panels 1A, 1B, and 2) or four (panel 3) laboratories used the NucliSens
HIV-1 QT assay (bioMérieux, Inc. [formerly Organon Teknika], Durham, N.C.)
with minor modifications. One DPS or DPS was placed in 9 ml of NucliSens lysis
buffer and rocked at room temperature for 2 h to elute the RNA from the filter
paper. Once the filter paper was removed, the manufacturer’s instructions were
followed for the remainder of the procedure.
Five (panels 1A and 1B) or six (panel 2) laboratories used a modified Ampli-
cor HIV-1 Monitor assay (version 1.0; Roche Diagnostics) to quantitate the
RNA in the blood and plasma spots. HIV RNA was eluted from the filter paper
by treatment with a chaotrope, organic reagent, and detergent (CORD) solution
consisting of 33% (vol/vol) buffered phenol (pH 4.3), 1.34 M guanidinium iso-
thiocyanate, 0.2% (vol/vol) Sarkosyl, 0.3% (vol/vol) sodium dodecyl sulfate, 0.2%
(vol/vol) mercaptoethanol, 0.6% (wt/vol) glycogen, and 8 mM sodium citrate.
The DBS or DPS was cut or punched into small pieces and incubated in 0.75 ml
of CORD reagent containing 0.5 g of tRNA and 3.3 l of the kit quantitation
standard at 56°C, with shaking, for 30 min. The RNA was then extracted from the
mixture with chloroform, followed by alcohol precipitation and elution with the
HIV-1 Monitor specimen diluent (100 l). Amplification and detection of the
extracted RNA (50 l) were performed according to the manufacturer’s guide-
lines. The CORD reagent was prepared by Roche Molecular Systems and dis-
tributed to the laboratories that used the HIV-1 Monitor assay.
Statistical methods. Data from the three panels were transformed to base 10
logarithms for analysis. The data for the HIV-negative specimens were excluded
from all of the analyses. Data from the NucliSens and Monitor assays were
analyzed separately. Linear regressions of the log10 estimated HIV RNA con-
centration on the log10 nominal HIV RNA concentration were used to analyze
the data for panels 1A and 1B. The analysis was restricted to six laboratories
from which results were obtained for both rounds of testing (Monitor assay, four
laboratories; NucliSens assay, two laboratories). Predictor variables were added
to the model to test for variations in the results between DBSs and DPSs,
between the two panels, or among laboratories. More complex predictors were
added to determine if differences between panels or between specimen types
varied over laboratories or if any of the differences varied with nominal concen-
tration.
Analysis of variance was used for panel 2. Indicator variables for the donor
were included in all models. Hematocrit-corrected estimates of the concentra-
tions from DBSs with those from DPSs were compared with estimates of the
concentrations from plasma in separate analyses. Predictors were added to the
models to determine if differences between specimen types varied among donors
or laboratories.
The stability of HIV RNA in stored DBSs and DPSs was assessed by using
regressions on the log10 estimated RNA concentration on time in storage and
donor to model the results for panel 3. The analysis was stratified by specimen
type (DPSs versus DBSs) and storage condition (room temperature versus
70°C) to form four separate regressions. Variables were added to the models
to determine if the rate of change in HIV RNA concentration in storage varied
among donors or laboratories.
In some cases, results that were below the limit of detection of an assay were
included in an analysis. Estimates that were below the limit of detection for the
NucliSens kit were set at 400 copies/ml. Estimates that were below the limit of
detection for the Monitor test were set at values that were calculated by substi-
tuting an optical density of 0.2 units for the optical density for the undiluted
amplified sample. This is the minimum RNA concentration that would have
produced a positive result by the Monitor test, given the results for the internal
quantitation standard in each assay.
RESULTS
Panels 1A and 1B were used to evaluate the technical per-
formance of the laboratories, focusing primarily on their abil-
ities to perform the DBS and DPS extractions and the quan-
titative RNA assays. One false-positive result was obtained by
the NucliSens assay (estimated RNA concentration, 420 cop-
ies/ml). Another was obtained by the Monitor assay (estimated
RNA concentration, 285 copies/ml).
The samples with nominal concentrations of 800 copies/ml
were excluded from the statistical comparisons of estimates of
the concentrations from DBSs and DPSs because nearly half of
the results were below the limits of detection of the two kits
(NucliSens assay, 8 of 12 from DPSs and 7 of 12 from DBSs;
Monitor assay, 9 of 19 from DPSs and 7 of 21 from DBSs).
Results at a nominal concentration of 4,000 copies/ml that
were below the limit of detection of the assay were included in
the analysis, as described earlier (Nuclisens assay, 4 of 12 from
DPSs and 2 of 12 from DBSs; Monitor assay, 1 of 22 from
DPSs and 3 of 21 from DBSs).
Log-log plots of the estimated HIV RNA concentrations
from DBSs against the nominal RNA concentrations are
shown separately for the NucliSens assay (Fig. 1A) and the
Monitor assay (Fig. 1B). On average, estimates by the Nu-
cliSens assay for panel 1A were 0.11 log10 (29%) higher than
estimates for panel 1B (P  0.011), and the results from DBSs
were, on average, 0.11 log10 (29%) higher than those from
DPSs. There was no evidence that the differences between
log-transformed estimates of the concentrations from the two
panels or two specimen types varied among nominal concen-
trations or among laboratories.
The results of the Monitor assay were more heterogeneous
than those of the NucliSens assay, which made the analysis very
difficult. The difference between estimates of the concentra-
tions from DBSs and DPSs depended on both the laboratory
and the panel that was considered (P  0.016). When the
results for DPSs and DBSs were analyzed separately, estimates
of the concentrations from DPSs in panel 1A were, on average,
0.27 log10 (86%) higher than those from DPSs in panel 1B (P
 0.001), with no evidence that the difference between panels
varied among laboratories or nominal concentrations. How-
ever, for DBSs, the differences between panels varied among
laboratories (P  0.001) and nominal concentrations (P 
0.005), making it very difficult to draw any general conclusions
from the data.
Log-log plots of median hematocrit-adjusted estimated HIV
RNA concentrations from DBSs in panel 2, for each donor in
each laboratory, against the median for plasma, for data com-
bined across laboratories, are shown separately for the Nu-
cliSens assay (Fig. 2A) and the Monitor assay (Fig. 2B). By the
NucliSens assay, the hematocrit-corrected estimates of the
concentrations from DBSs were, on average, 0.078 log10
(16.5%) lower than those from plasma (P  0.16), with no
detectable variation in the difference among laboratories (P 
0.39) or donors (P  0.49). Similar results for panel 2 were
seen for the comparison of DPSs and plasma by the NucliSens
assay (data not shown).
Differences between estimates of the concentrations from
DBSs and plasma by the modified Monitor assay varied among
the six laboratories (P  0.001). No differences between the
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two sample types were noted in two laboratories (P  0.24 and
P  0.17), but estimates of the concentrations from DBSs
were, on average, 0.22 log10 (40%) lower than those from
plasma in a third laboratory (P  0.04). In each of the other
three laboratories, the difference between DBSs and plasma
varied among donors. The differences (concentrations in DBS
 concentrations in plasma) ranged from 0.44 to 0.82 log10
across donors and laboratories, even though the specimens
from the three donors were assayed in the same run in each
laboratory. For the Monitor assay, the difference between es-
timates of the concentrations from DPSs and plasma varied
among laboratories (P  0.002) but not among donors (P 
0.20) (data not shown).
Panel 3 was designed to evaluate the effects of long-term
storage on RNA levels in DBSs and DPSs (Fig. 3) and was
tested only by the NucliSens assay. Data through 52 weeks of
storage were obtained from three laboratories, and data
through 26 weeks of storage were obtained from a fourth
laboratory. The results for one of three HIV-infected donors
were excluded because 40% of the values were below the limit
of detection of the assay. Values below the limit of detection
were obtained for DBSs and DPSs stored at both temperatures
and for DBSs and DPSs at all time points for this donor.
Rates of change in the log10 RNA concentration varied
among the laboratories for DBSs stored at both room temper-
ature (P  0.01) and 70°C (P  0.001) and for DPSs stored
at 70°C (P  0.001), but there was little or no evidence of
substantial loss of RNA from these samples in any of the
laboratories. The rates of change in the RNA concentration
differed from zero for only 5 of 12 samples (P  0.02 for each
versus P  0.10 for changes that were not statistically signifi-
cant). These occurred at 70°C at four laboratories and at
ambient temperature at only one laboratory. The changes were
actually positive at four of the five laboratories. The one sta-
tistically significant negative change indicated a 52-week loss of
only 7% at 70°C. No variation in the rate of change in RNA
concentration in DPSs at room temperature was detected
among the laboratories. The 52-week loss averaged 2.4%, but
this was not statistically significant (P  0.18).
DISCUSSION
Both the NucliSens assay and a modified version of the
Monitor assay can be used to quantitate HIV-1 RNA from
DBSs or DPSs, although in this evaluation there was consid-
erably less variation with the NucliSens assay. Detection of
HIV RNA was linear over a dynamic range extending from
4,000 to 500,000 HIV-1 RNA copies/ml.
Variation in the Monitor assay made analysis difficult, and
the sources of this variation were difficult to pinpoint. The
FIG. 1. Log10 estimated HIV RNA concentrations plotted against log10 nominal HIV RNA concentrations for the NucliSens and Monitor
assays. Panel 1 specimens were tested on two different occasions (round A and round B). The horizontal line represents the median estimated
concentration at each nominal concentration.
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variability might be due to the modified RNA extraction
method that had to be used for the dried spots. Phenol-chlo-
roform extractions are more technically demanding, and dif-
ferences in the recovery of the appropriate phase during the
extraction may affect HIV RNA recovery. Potential sources of
variation include the retention of various levels of inhibitors
such as heme and iron, errors during the RNA extraction, and
reagent or kit variability. Furthermore, the reagents used for
the modified Monitor extraction method were in their initial
stages of development and, hence, were not completely opti-
mized. To the best of our knowledge, Roche no longer sup-
ports this application and these reagents are not available
commercially.
On the other hand, the Monitor assay appeared to be some-
what more sensitive, particularly in detecting specimens with
lower viral loads. This is probably a function of the differences
in the amount of the actual RNA eluate that went into the
amplification steps for the two assays. For the Monitor assay,
the RNA was eluted in 100 l of diluent and half was used for
amplification. The specimen input for the plasma spot was
equivalent to 25 l, a volume comparable to that used for the
standard Monitor assay. The NucliSens assay elutes the RNA
into 50 l of diluent, but only 5 l is used for amplification.
The specimen input for the plasma spot was equivalent to 5 l,
which is 1/4 to 1/20 the volume used for plasma analysis by the
NucliSens assay. The NucliSens assay could potentially be
made more sensitive by reducing the elution volume used dur-
ing the extraction.
HIV RNA was stable in DBSs and DPSs stored at room
temperature and at 70°C for at least 1 year (Fig. 3), and
possibly longer. The differences observed in our experiments
were probably due to factors such as interassay variation
and/or lot-to-lot variation in the kits and are not considered to
be clinically significant. Interassay variation would account for
the small positive changes if results in a given laboratory were
unusually low at early time points or unusually high at later
time points, as was the case in some laboratories. These data
confirm those of O’Shea et al. (17) regarding the stability of
HIV RNA dried on Guthrie cards. Previous results suggesting
that HIV RNA was lost with increasing time of storage (14)
was probably due to differences in the paper used.
Although the sensitivity of an RNA assay with DBSs may
never reach the sensitivity of an assay with whole plasma, it
may still be sensitive enough given recent changes in treatment
guidelines (patients should be treated when viral load is
50,000 copies/ml or when the CD4 count is 350 cells/mm3).
In this study we were able to reliably measure viral loads of
4,000 copies/ml or greater. The potential to improve this sen-
sitivity exists and may be warranted. DBSs offer an easy and
inexpensive means for the collection and storage of blood,
since they are stable and noninfectious and can easily be sent
to centralized testing laboratories for analysis. DBSs clearly
FIG. 2. Results for panel 2 showing the median log10 hematocrit-adjusted (Hct Adj.) estimated HIV RNA concentrations in DBSs in each
laboratory plotted against the median log10 estimated HIV RNA concentrations in plasma for all laboratories in which the same kit was used. The
dotted line represents the line of equivalence.
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provide the perfect means for the collection of specimens un-
der field conditions for the diagnosis of HIV infection and the
monitoring of antiretroviral therapy and vaccine efficacy.
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